Capricor Therapeutics, Inc.
CAPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133869
No open-market purchases or sales by Capricor Therapeutics, Inc. insiders were filed in the last 90 days; 169 institutions reported holding it in 13F filings for Q2 2026, worth $941.6M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Capricor Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 121 | 1 | 108 | −12 |
| Shares | 18.3M | 52 | 13.7M | −4.59M (−25.0%) |
| Value | $174.0M | $493 | $136.5M | −$37.5M (−21.6%) |
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Capricor Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| National Bank of Canada | 168,700 | $1.68M | 0.00% |
| Marshall Wace, LLP | 80,187 | $796.3K | 0.00% |
| Propel Bio Management, LLC | 70,000 | $695.1K | 0.84% |
| Two Sigma Advisers, LP | 60,622 | $602.0K | 0.00% |
| Wolverine Trading, LLC | 46,926 | $523.2K | 0.01% |
| Simplify Asset Management Inc. | 40,000 | $397.2K | 0.02% |
| LPL Financial LLC | 17,721 | $176.0K | 0.00% |
| Ellerson Group Inc | 17,100 | $169.8K | 0.12% |
| UBS Oconnor LLC | 17,054 | $169.3K | 0.00% |
| Nomura Holdings Inc | 14,267 | $141.7K | 0.00% |
| D. E. Shaw & Co., Inc. | 10,733 | $106.6K | 0.00% |
| Sherbrooke Park Advisers LLC | 10,472 | $104.0K | 0.05% |
| State of Wyoming | 2,216 | $22.0K | 0.00% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 448 | $4.00K | 0.00% |
| Allworth Financial LP | 65 | $646 | 0.00% |
| IFP Advisors, Inc | 0 | $159 | 0.00% |
| Aquatic Capital Management LLC | 1 | $10 | 0.00% |
Sold out (29)
Institutions that held Capricor Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (1)
Institutions that held Capricor Therapeutics, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Lindbrook Capital, LLC | 52 | $493 |